Prognosis of Behavioral Addiction in Parkinson's Disease (PROBA-PD)
Our hypothesis is that the conventional treatment of Behavioral Addiction in Parkinson's disease is often not effective, and that affects the motor aspects (worsening akinéto-rigid syndrome and / or worsening of dyskinesia due to higher levodopa doses to compensate for the drop in behavioral addictions) and non-motor (withdrawal syndrome dopamine agonist) anxiously including apathy.
Our goal is to describe the natural history of Behavioral Addiction under the effect of the evolution of the disease and adapt treatment according to the prior art, through a study of a larger population of patients than in the few published studies.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
- Survival time before disappearance of behavioral addiction defined by a score of less than 2 on the scale of behavioral assessment of Parkinson's disease [ Time Frame: 12 months after selection ]
|Study Start Date:||February 2016|
|Estimated Study Completion Date:||January 2021|
|Estimated Primary Completion Date:||January 2021 (Final data collection date for primary outcome measure)|
|- Patients with behavioral addiction|
|- Patients with no behavioral addiction|
Please refer to this study by its ClinicalTrials.gov identifier: NCT02671240
|Contact: Mathieu ANHEIM, MD, PhD||33 (0)3 88 12 85 firstname.lastname@example.org|
|Study Director:||Mathieu ANHEIM, MD, PhD||University Hospital, Strasbourg, France|